Friday, Aug 19, 1983

Genentech, Inc. and Granada Announce bovine interferon R&D Agreement

South San Francisco, Calif. -- August 19, 1983 --

Genentech, Inc. and Granada Corporation today announced a $20 million research and development agreement established for the purpose of pursuing the application of Genentech's bovine interferons for use in the cattle industry. It is expected that bovine interferons for use in the cattle industry. It is expected that bovine interferons will be marketed throughout the United States and Canada.

Bovine interferons are naturally-occurring proteins of the immune system in cattle. Genentech uses recombinant DNA technology to manufacture these proteins for use as animal health care products with potentially broad applications.

Initial animal testing indicates that bovine interferons offer possibility as potent new aids in the management of many viral-related diseases, including the disease complex commonly called "shipping fever" (Bovine Respiratory Disease). This disease complex results in major losses for U.S. cattlemen: up to one-third of all animals in feedlots are affected by shipping fever. Estimated costs due to weight loss and death exceed $250 million annually.

Genentech, Inc. headquartered in South San Francisco, CA, is a leader in the development, manufacture and marketing of recombinant DNA products for pharmaceutical, agricultural and industrial chemicals markets.

Granada Corporation, whose offices are in Houston, TX, is a leading international technical service contractor operating in the field of agriculture, and specializing in beef and dairy cattle improvement through genetic research and development.

# # #